Candidate gene and mechanism investigations in congenital obstructive nephropathy based on bioinformatics analysis

GUANGDA XIN¹, RUI CHEN² and XIAOFEI ZHANG²

Departments of ¹Nephrology and ²Pediatrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China

Received November 12, 2017; Accepted June 7, 2018

DOI: 10.3892/mmr.2018.9284

Abstract. The aim of the present study was to explore the candidate genes, chemicals and mechanisms of congenital obstructive nephropathy (CON). The gene expression profiles of GSE48041, including 24 kidney tissue samples from megabladder (mgb-/-) mouse were downloaded from the Gene Expression Omnibus database. Samples were divided into 4 groups: Control, mild, moderate and severe. Differentially expressed genes (DEGs), protein-protein interaction network, Kyoto Encyclopedia of Genes and Genomes pathways and transcription factor (TF)-target gene analyses were performed on Set 1 (mild, moderate and severe groups), while Gene Ontology (GO) function enrichment analysis and chemical investigation were performed on Set 2 (severe group). A total of 187 and 139 DEGs were obtained in Set 1 and Set 2, respectively. Chemical carcinogenesis [enriched by genes such as Carbonyl reductase 1 (CBRI)] was one of the most prominent pathways in Set 1. GO analysis for Set 2 revealed that DEGs were mainly assembled in functions such as cellular response to interleukin-1 and cellular response to tumor necrosis. Furthermore, genes such as Fos Proto-Oncogene (FOS) were co-regulated by TFs including RNA polymerase II subunit A (Polr2a) and serum response factor (Srf). Chemical cyclosporine served the most important role in Set 2 by targeting several DEGs in Set 2. DEGs such as CBRI and FOS, TFs including Polr2a and Srf, and pathways such as chemical carcinogenesis may serve important roles in the process of CON. Interleukin-1 and tumor necrosis function may be novel targets for CON gene therapy. Furthermore, cyclosporine may be a promising option for future CON therapy.

Introduction

Congenital obstructive nephropathy (CON) is a main cause of kidney insufficiency in child and infant (1). It is associated with various diseases, such as prune belly syndrome (2). As a result, CON generates a huge social burden especially in the morbidity and mortality (2). The different challenges associated with CON in areas like diagnose and therapy highlight the importance of the molecular mechanism of CON (3). Thus, the emerging theories of the biology of CON suggest new targets for therapeutic interventions (4).

Identification of novel biomarkers provides prognostic value for this process remains a major goal in the study of kidney disease (5). In renal and urinary tract, previous study showed that disruption of angiotensin type 2 receptor (AGTR2) induced a huge scale of anomaly (6). Meanwhile, the Monocyte chemotactic protein 1 (MCP-1) as well as the Epidermal growth factor (EGF) seem to be involved in the pathogenesis of tubulointerstitial damage of CON, and their urine excretion may serve as a powerful prognostic marker for this form renal disease (7). Not only gene, but also pathways enriched by differentially expressed genes (DEGs) are closed related with CON. Previous study demonstrated that TGF-β signaling pathway plays an important role in regulating kidney injury process following by obstruction (8). In a rat model, Hermens et al. (9) show that there is an age-dependent role of Wnt signaling pathway in the pathophysiology of CON. Despite of revealing the potential genes or pathways, understanding the molecular mechanism of CON also brings a breakthrough for the novel treatment of CON (10). The development of biomarkers contribute to molecular therapies of CON (11). However, the molecular mechanisms underlying these histologic changes are still poorly defined.

To better understand the pathophysiology of CON, Brian Becknell and his colleagues evaluated the global transcription in kidneys with graded hydronephrosis in the megabladder (mgb2/2) mouse (12). Based on normal, mild, moderate, and severe mouse models, they prove that the development of progressive hydronephrosis can result in renal adaptation, including significant changes in the morphology and potential functionality of the renal urothelium. However, the co-regulated gene in all models, transcription factor (TF) associated with DEGs, gene expression in severe disease status, as well as the potential chemicals for CON treatment are still unclear. In the
current study, a bioinformatics research was designed based on the gene expression profile provided by Becknell et al. (12). Then, investigations of DEGs, function and pathway enrichment, protein-protein interaction network (PPI) analyses, as well as TF-target gene regulatory network were performed in all disease statuses. Furthermore, the chemical-gene interaction network in severe models were also investigated. We aimed to explore the potential pathogenesis of CON and provided information about novel gene targets, as well as chemicals for CON treatment.

Materials and methods

Microarray data. Expression data of GSE48041 (12), sequenced on the platform of GPL10787 Agilent-028005 SurePrint G3 Mouse GE 8x60K Microarray, were obtained from the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/). A total of 24 kidney tissue samples from control and megabladder (mgb-) mouse aged 23-30 days were included in this dataset, and hydrencephrosis was induced by renal ultrasound as previously reported (13). According to the hydrencephrosis degrees (www.sfu-urology.org/sfu_hydrone_grading.cfm), animals were divided into 4 groups: Control (n=6), mild (n=7), moderate (n=5) and severe (n=6) according to their disease stages.

Data preprocessing. The preprocessing were performed based on robust multi-array average (RMA) method (14) in Affy package (15) in R (v.3.10.3, Bioconductor.org/biocLite.R), Contents of processing included background correction microarray expression intensities, normalize the expression within each array, and expression calculation. The probe ID was convert to the gene symbol based on the chip platform annotation files.

DEGs analysis. Classical Bayes method in Linear Models for Microarray Data (limma) package (16) of R was used to reveal DEGs by comparing expression value among samples from three comparisons; Mild vs. control, moderate vs. control, and severe vs. control. P-value <0.05 and log2 log fold change (FC)≥1 were selected as the cut-off criteria for DEG screening.

VennPlot analysis of DEGs. VENNY (v.2.1) (17) is an online tool used for Venn diagram analysis based on gene expression value. The number of up-regulated, down-regulated, and contra-regulated genes can be marked by VennPlex. In the present study, VennPlex software was used to investigate the difference of DEGs among 3 comparative groups. Then, the co-regulated DEGs (Set 1) and severe group DEGs (Set 2) were selected for further investigation.

Enrichment analysis of DEGs. The Database for Annotation, Visualization, and Integrated Discovery (DAVID; v.6.8) (18) provides a synthetic set of functional annotation tools for users for revealing the biological significances among huge scale of genes. Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis were performed using DAVID online tool (19). GO functional categories including molecular function (MF), biological process (BP), and cellular component (CC) (20). In the present study, GO functions assembled by DEGs in severe group, as well as KEGG pathways enriched by the co-regulated DEGs were investigated. P-value <0.05 and enriched gene numbers (count) ≥2 were considered as cut-off values.

PPI network investigation. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; v.10.0) is an online tool for the predication of PPI based on a large scale of biological database (21). In the present study, STRING was used to predict the interaction relations between DEGs corresponding coding proteins. PPI were revealed based on the STRING database with score (median confidence)=0.4, and nodes represent DEGs in the PPI interaction. The degree was defined as the number of the connections for the target proteins. Cytoscape software (v.3.2.0) (22,23) was used for the visualization of PPI network obtained above. Then, the CytoNCA software (v.2.1.6, apps.cytoscape.org/apps/cytonica) (24) was used for the nodes topological analysis (Parameter: Without weight). Furthermore, the sub-networks with score >4.5 were identified by MOCDE (v.1.4.2; apps.cytoscape.org/apps/MCODE) (23) plugin in Cytoscape software.

TF-target gene regulatory network construction. TF is an important class of participators in the regulation of gene expression. Analysis of TF binding sites is of great significance for the study of gene regulation system. In the current research, the TFs-co-regulated DEGs network was constructed with iRegulon (25) (v.1.3, apps.cytoscape.org/apps/iRegulon). The Parameters of this analysis were set as: Minimum identity between orthologous genes=0.05, and maximum false discovery rate (FDR) on motif similarity=0.001. TF-target gene relations with normalized enrichment score (NES) >4 were considered as the meaningful results.

Chemical-DEGs interaction network construction. Comparative Toxicogenomics Database (CTD) provides relationships, such as chemical-gene/protein interactions, chemical-disease as well as gene-disease (26). Relationship between disease (Nephrosis, congenital) associated chemical-gene or interactions was revealed by CDT. Then Chemical-DEGs interaction network was constructed by Cytoscape software.

Results

DEGs investigation in mild, moderate and severe groups. Considering a huge amount of calculation in gene expression profile, the original data was analyzed and filtered. The results revealed that totally 220 up-regulated DEGs and 225 down-regulated DEGs were obtained in the mild group. In the moderate group, there were 375 up-regulated DEGs and 142 down-regulated DEGs screened out. Furthermore, a total of 484 up-regulated DEGs and 280 down-regulated DEGs uncovered in the severe group.

VennPlot analysis. VennPlot for DEGs in the mild, moderate, and severe groups were investigated in the present
The results revealed 187 co-regulated DEGs in Set 1, including 87 up-regulated DEGs and 100 down-regulated DEGs. In Set 1, *Serpina6, Hpd*, and *Nr4a1* were the 3 most outstanding up-regulated genes, while *Proz, 4122401K19Rik*, and *Nudt19* were the 3 most outstanding down-regulated genes. Meanwhile, there were 139 DEGs in Set 2, including 121 up-regulated DEGs and 18 down-regulated DEGs. In Set 2, *Sprr2f, Lcn2* and *Saa2* were the 3 most outstanding up-regulated gene, while *Symbol, Vps8* and *Ang2* were the 3 most down-regulated gene.

KEGG and GO enrichment analysis. The KEGG analysis of DEGs in Set 1 showed that a total of 16 pathways were significantly enriched (Table I). The up-regulated DEGs were mostly enriched in TNF signaling pathway (muu04668, P=3.59x10^-4), while the down-regulated DEGs were mainly assembled in Retinol metabolism (muu00830, P=1.36x10^-7). Among these pathways, Chemical carcinogenesis (muu05204, Gene: *CBR1, UGT2B38, GSTA2, UGT2B37 and UGT2B36*) was the common pathway in all 3 group of Set 1. The detail pathway map of Chemical carcinogenesis was showed in Fig. 2.
GO functional analysis was performed in the severe group DEGs. With count number >10, the top 10 of BP, CC, and MF functions were revealed, respectively. The DEGs in the severe group was mainly assembled in functions like inflammatory response (BP, GO: 0006954, P=1.43x10^{-3}), cellular response to interleukin-1 (BP, GO: 0071347, P=8.87x10^{-3}), cellular response to tumor necrosis (BP, GO: 0071356, P=6.34x10^{-4}), extracellular region (CC, GO: 0005576, P=3.53x10^{-7}), and cytokine activity (MF, GO: 0005125, P=7.63x10^{-5}). The detail information was showed in Fig. 3.

PPI network and modules analysis. To dig out the potential interactions of the DEGs, PPI network and related modules were constructed based on the protein interactions of DEGs. A total of 102 nodes (Jun, Fos, Ptgs2, Ugt2b37, Junb, Atf3, Cyp4a12a, Adh1, Ugt2b5, Egr1, etc.) and 320 interactions were identified in the PPI network of Set 1. With score >4.5, 2 modules were further obtained from the Set 1 PPI network. There were 13 nodes (Jun, Fos, Ptgs2, Junb, Atf3, Egr1, Dusp1, Nr4a1, Zfp36, Btg2, etc.) and 60 interactions in module a (score=10), while 8 nodes (Ugt2b5, Cyp2j13, Acsm3, Cyp4a12b, Cyp4a14, Cyp4b1 Slc22a30 and Slc7a13) and 20 interactions contained in module b (score=5.714) (Fig. 4). Furthermore, there were a total of 73 nodes (Ccl2, Timpl, Acta2, Spp1, Actg2, Thbs1, Edn1, Aldh1a1, Mmp3, Aldh1a7, etc.) and 143 interactions included in the PPI network of Set 2. With score >4.5, one module was further obtained from the Set 2 PPI network. A total of 5 nodes (Aldh1a1, Aldh1a7, Aifm3, Hbb-b1 and Acad9) and 9 interactions were revealed in the module of Set 2 (Fig. 5).

TF-target gene regulatory network analysis. By using the iRegulon software, 2 TFs (Polr2a and Srf) were obtained from the Set 1 PPI network. To further investigate the relationship between TFs and their target genes, the TF-target gene network was visualized by cytoscape software. With NES >4, the results showed that there were totally 52 regulatory relations contained in this network. Some genes like FOS were co-regulated by both Polr2a and Srf. The detail information was showed in Fig. 6.

Chemical-gene interaction network analysis. The present study revealed totally 12012 chemical-gene interactions related to Nephrosis or congenital. Among these interactions, totally 60 interactions were matched with the 139 DEGs in Set 2. The results showed that Cyclosporine was the most important chemical that target with either the most number of up-regulated or down-regulated DEGs in Set 2. Detailed information was listed in Table II.

Discussion

CON is the leading cause of chronic kidney disease in child. However, the molecular mechanisms underlying disease progression are still poorly defined. To reveal the potential genes or pathways associated with CON, the present bioinformatics study was performed on mild, moderate, and severe CONs. The results showed that totally 187 and 139 co-regulated DEGs were obtained in Set 1 and Set 2, respectively. KEGG analysis for Set 1 showed that DEGs were mainly enriched in pathways like chemical carcinogenesis. Meanwhile, the GO analysis for Set 2 showed that DEGs were mainly assembled in functions like cellular response to interleukin-1 and cellular response to tumor necrosis. Two modules in Set 1 and one module in Set 2 were revealed based on PPI network analysis. Furthermore, the genes like FOS were co-regulated by TFs like Polr2a and Srf. Cyclosporine was the most important chemical that target with DEGs in Set 2.

Based on the Set 1 (including all disease status like mild, moderate and severe), KEGG pathway analysis, PPI network analysis, and TF-target investigation were carried out in this study to provide a potential mechanism understanding for the process of CON. Chemical carcinogenesis is a process that the cells need genetic and epigenetic variations based on elements including oncogenes and tumor suppressors (27,28). Carbonyl reductase 1 (CBR1) metabolized by the body many...
Figure 2. Kyoto Encyclopedia of Genes and Genomes pathway map for chemical carcinogenesis. Red represents the upregulated genes, while green represents the downregulated genes.
Figure 3. GO enrichment analysis for DEGs in the severe group. The top 10 functions associated with BP. The top 10 functions associated with CC. The top 10 functions associated with MF. The y-axis represents the count number of functions. Fold line represents the -log10 (P-value). GO, gene ontology; DEGs, differentially expressed genes; BP, biological process; CC, cellular component; MF, molecular function.

Figure 4. PPI network and modules of common DEGs in the mild, moderate and severe group. Red circles represent the upregulated genes and purple diamonds represent the downregulated genes. A bigger node indicates a higher degree. PPI, protein-protein interaction; DEGS, differentially expressed genes.
toxic environmental quinones and pharmacological relevant substrates, such as the anticancer doxorubicin (27). Previous study has shown that CBRI is vital for the cell protection in functions like oxidative stress and apoptosis (29). Pathway analysis showed that the chemical carcinogenesis was the common pathway enriched by both up- and down-regulated DEGs (especially CBRI in Set 1). Thus, we speculated that DEGs like CBRI in chemical carcinogenesis pathway might be the potential pathogenesis of CON. However, the related study associated with chemical carcinogenesis pathway about CBRI and CON is very rare. Furthermore, c-Fos (FOS) gene has been considered as the regulators of cell proliferation, differentiation, transformation, and apoptotic cell death (30,31). Otsuka et al (32) indicates that the expression of FOS is potentially an early indicator of late radiation damage to the kidney. In rats model, previous study indicated that the renoprotective effects of drugs partly through inhibiting the upregulation of FOS mRNA and protein in renal cortices (33). In the present study, the PPI network analysis showed that FOS was one of the most outstanding DEGs in Set 1. Interestingly, the TF-target gene network in this study showed that FOS was the co-target gene of Polr2a and Srf. Thus, we speculated that DEGs like FOS might play an important role in the process of CON via TFs like Polr2a and Srf. However, the related study associated with FOS and CON is very rare. Thus, an additional research with a wide scale of gene expression analysis is necessary to confirm this speculation.

Based on Set 2 (only severe group), GO function analysis and chemical-gene interaction network investigation in this study were performed and intended to provide a potential therapy strategy for CON. Interleukin-1 family plays a vital role in the immune and inflammatory responses regulation (34). Previous study showed that the protective effect of interleukin-1 in renal injury might be induced by reducing the induction of the nuclear factors (35). Actually, Pindjakova et al (36) indicate that the production of interleukin-1 based on the resident dendritic cells enhances the situation of acute kidney injury. Moreover, tumor necrosis factor (TNF) is a superfamily of cytokines that can lead to cell death, and it is a potent pyrogen that can be caused by stimulation of interleukin-1 secretion (37).
Meldrum et al (38) prove that TNF-α mediates renal tubular cell apoptosis in the process of obstructive uropathy. Recent study indicates that the production of TNF-α by macrophages take part in the progression of renal injury (39). Actually, interleukin-1 and TNF-α gene polymorphism are associated with the susceptibility, disease activity and long-term outcome in human nephropathy (40). In the current research, the results of GO analysis showed that cellular response to interleukin-1 and cellular response to tumor necrosis is two of most outstanding function assembled by DEGs. Thus, we speculated that these two functions might be vital for the process of severe CON. The deteriorated or even cancerization might take place in severe CON, which needed an early therapy intervention. Furthermore, cyclosporine, also spelled ciclosporin or cyclosporin, is an immunosuppressant medication and natural product (41). As an immunosuppressant with therapeutic indications in various immunological diseases, the use of cyclosporine is reported to be associated with chronic nephropathy (42). In the present study, cyclosporine was the most outstanding chemical associated with DEGs identified in severe CON. Thus, cyclosporine might still be the preferences for the therapy of CON. However, due to the negative effects of cyclosporine in CON clinical treatment, a more effective drug with less adverse reaction is needed.

However, there were still some limitations in this study. First, findings in the present study were all analyzed by bioinformatics methods, and experimental validations were deficient. Second, parameters used in in silico analyses were set manually, and some results might be missed or

| Gene   | Chemical name | Description | Gene   | Chemical name | Description | Gene   | Chemical name | Description |
|--------|---------------|-------------|--------|---------------|-------------|--------|---------------|-------------|
| ACTA2  | Cyclosporine  | UP          | EREG   | Cyclosporine  | UP          | RGS16  | Cyclosporine  | UP          |
| ACTG2  | Cyclosporine  | UP          | FGB    | Cyclosporine  | UP          | RHOU   | Cyclosporine  | UP          |
| AIFM3  | Cyclosporine  | DOWN        | FOXA1  | Cyclosporine  | UP          | S100A6 | Cyclosporine  | UP          |
| ALDH1A1| Cyclosporine  | UP          | FOXQ1  | Cyclosporine  | UP          | SAA2   | Cyclosporine  | UP          |
| APOC2  | Cyclosporine  | UP          | GDF15  | Cyclosporine  | UP          | SAMD5  | Cyclosporine  | UP          |
| BCAS1  | Cyclosporine  | UP          | GPR87  | Cyclosporine  | UP          | SDC1   | Cyclosporine  | UP          |
| BCL2L14| Cyclosporine  | UP          | IGFBP1 | Cyclosporine  | UP          | SERPIN3A | Cyclosporine  | UP          |
| CAPG   | Cyclosporine  | UP          | IGFBP6 | Cyclosporine  | UP          | SLC16A3| Cyclosporine  | UP          |
| CCL2   | Cyclosporine  | UP          | ITGA11 | Cyclosporine  | UP          | SLC17A3| Cyclosporine  | DOWN        |
| CCL6   | Cyclosporine  | UP          | LCN2   | Cyclosporine  | UP          | SLC39A4| Cyclosporine  | UP          |
| CD14   | Cyclosporine  | UP          | LOX    | Cyclosporine  | UP          | SPP1   | Cyclosporine  | UP          |
| CES1E  | Cyclosporine  | DOWN        | LTBP2  | Cyclosporine  | UP          | TACSTD2| Cyclosporine  | UP          |
| CLDN4  | Cyclosporine  | UP          | MKD    | Cyclosporine  | DOWN        | TAGLN  | Cyclosporine  | UP          |
| CNN1   | Cyclosporine  | UP          | MFAP5  | Cyclosporine  | UP          | TGFB3  | Cyclosporine  | UP          |
| COL27A1| Cyclosporine  | DOWN        | MGST2  | Cyclosporine  | UP          | THBS1  | Cyclosporine  | UP          |
| CP     | Cyclosporine  | UP          | MMP3   | Cyclosporine  | UP          | TIMP1  | Cyclosporine  | UP          |
| CPE    | Cyclosporine  | UP          | MMP7   | Cyclosporine  | UP          | TRPV6  | Cyclosporine  | UP          |
| CTSE   | Cyclosporine  | UP          | OSMR   | Cyclosporine  | UP          | TUBB2B | Cyclosporine  | UP          |
| EDN1   | Cyclosporine  | UP          | PAK3   | Cyclosporine  | UP          | UCHL1  | Cyclosporine  | UP          |
| ENTPD3 | Azathioprine  | UP          | PLAUR  | Cyclosporine  | UP          | UPK3A  | Cyclosporine  | UP          |

UP, upregulated; DOWN, downregulated.
overemphasized. Therefore, further experimental validations in both in vivo and in vitro were required in the future.

In conclusion, the DEGs like CBR1 and FOS, TFs like Polr2a and Srf, as well as pathways like chemical carcinogenesis might play important roles in the process of CON. Interleukin-1 and tumor necrosis function were associated with the deteriorate of CON, and might be novel targets for CON treatment. Furthermore, a more effective drug with less adverse reaction for severe CON is needed.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

GX contributed to the conceptualization of the research. GX and RC acquired the data and performed the analysis. RC and XZ interpreted the data. GX wrote the manuscript, and XZ revised the manuscript for important intellectual content.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Piepsz A, Ham H and Josephson S: RE: Biomarkers of congenital obstructive nephropathy: Past, present and future. J Urol 173: 2207-2208, 2005.
2. Ingraham SE and McHugh KM: Current perspectives on congenital obstructive nephropathy. Pediatr Nephrol 26: 1453-1461, 2011.
3. Chevalier RL, Thornhill BA, Forbes MS and Kiley SC: Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy. Pediatr Nephrol 25: 687-697, 2010.
4. Liapis H: Biology of congenital obstructive nephropathy. Nephron Exp Nephrol 93: e67-e91, 2003.
5. Chevalier RL: Prognostic factors and biomarkers of congenital obstructive nephropathy. Pediatr Nephrol 31: 1411-1420, 2016.
6. Hahn H, Ku SE, Kim KS, Park YS, Yoon CH and Cheong HI: Implication of genetic variations in congenital obstructive nephropathy. Pediatr Nephrol 20: 1541-1544, 2005.
7. Grandaliano G, Gesualdo L, Bartoli F, Ranieri E, Monno R, Leggio A, Paradies G, Caldarulo E, Infante B and Schena FP: MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int 58: 182-192, 2000.
8. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, Kaneko K, Yamashiro Y, Ogawa H and Nakao A: Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 66: 597-604, 2004.
9. Herrmans JS, Thelen P, Ringert RH and Seseke F: Alterations of selected genes of the Wnt signal chain in rat kidneys with spontaneous congenital obstructive uropathy. J Pediatr Urol 3: 335-342, 2007.
10. Chevalier RL: Promise for gene therapy in obstructive nephropathy. Kidney Int 66: 1709-1710, 2004.
11. Chevalier RL: Obstructive nephropathy: Towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2: 157-168, 2006.
12. Becknell B, Carpenter AR, Allen JL, Wilhide ME, Ingraham SE, Hains DS and McHugh KM: Molecular basis of renal adaptation in a murine model of congenital obstructive nephropathy. PLoS One 8: e72762, 2013.
13. Carpenter AR, Becknell B, Ingraham SE and McHugh KM: Ultrasound imaging of the murine kidney. Methods Mol Biol 886: 403-410, 2012.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Bioinformatics 4: 249-264, 2003.
15. Gattier L, Cope L, Bolstad BM and Irizarry RA: aaffy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315, 2004.
16. Smyth GK: Limma: Linear models for microarray data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Statistic for Biology and Health. Gentleman R, Carey VJ, Huber W, Irizarry RA and Dudoit S (eds). Springer, New York, NY, pp397-420, 2005.
17. Oliveros JC: Venny. An interactive tool for comparing lists with Venn diagrams. BioinfoGP of CNB-CSIC, http://bioinfo gp.cnb.csic.es/tools/venny/index.ht. Accessed July 1, 2017.
18. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
19. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery, Genome Biol 4: P3, 2003.
20. Gene Ontology Consortium: The gene ontology in 2010: Extensions and refinements. Nucleic Acids Res 38 (Database Issue): D331-D335, 2010.
21. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43 (Database Issue): D447-D452, 2015.
22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504, 2003.
23. Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and Arai AE: Multi-Contrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: A clinical validation study. J Cardiovasc Magn Reson 14: 83, 2012.
24. Tang Y, Li M, Wang J, Pan Y and Wu FX: CytoNCA: A cyto- scape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems 127: 67-72, 2015.
25. Janký R, Verfaillie A, Imrichová H, Van de Sande B, Standaert L, Janky R, Verfaillie A, Imrichová H, Van de Sande B, Standaert L, Christiaens V, Hulselman G, Herten K, Naval Sanchez M, Potier D, et al: iRegulon: From a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol 10: e1003731, 2014.
26. Davis AP, Grondin CJ, Lennon-Hopkins K, Saraceni-Richards C, Sciaky D, King BL, Wiegers TC and Mattingly CJ: e1003731, 2014.
27. Arl V, M, Zuo J, Trenz K, Roufosse CA, Lord GM, Netter J, Schmeiser HH, Hollstein M and Phillips DH: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43 (Database Issue): D447-D452, 2015.
28. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504, 2003.
29. Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and Arai AE: Multi-Contrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: A clinical validation study. J Cardiovasc Magn Reson 14: 83, 2012.
20. Tang Y, Li M, Wang J, Pan Y and Wu FX: CytoNCA: A cyto-scene plugin for centrality analysis and evaluation of protein interaction networks. Biosystems 127: 67-72, 2015.
21. Janký R, Verfaillie A, Imrichová H, Van de Sande B, Standaert L, Christiaens V, Hulselman G, Herten K, Naval Sanchez M, Potier D, et al: iRegulon: From a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol 10: e1003731, 2014.
22. Davis AP, Grondin CJ, Lennon-Hopkins K, Saraceni-Richards C, Sciaky D, King BL, Wiegers TC and Mattingly CJ: The comparative toxicogenomics database's 10th year anniversary: Update 2015. Nucleic Acids Res 43 (Database Issue): D914-D920, 2015.
23. Arl V, M, Zuo J, Trenz K, Roufosse CA, Lord GM, Netter J, Schmeiser HH, Hollstein M and Phillips DH: Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer 128: 21-32, 2011.
24. Jin K, Su KK, Li T, Zhu QX, Wang Q, Ge RS, Pan ZF, Wu BW, Ge LJ, Zhang YH, et al: iRegulon: From a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol 10: e1003731, 2014.
29. Ismail E, Al-Mulla F, Tsuchida S, Suto K, Motley P, Harrison PR and Birnie GD: Carbonyl reductase: A novel metastasis-modulating function. Cancer Res 60: 1173-1176, 2000.

30. Gao S, Tang K, Zhang J, Yang Z, Cui H, Li P, Tang H and Zhou M; Department of Orthopedics, Orthopedic Center of Chinese PLA, Southwest Hospital, Third Military Medical University; Department of Neurobiology, Third Military Medical University: Effect of cyclic stretch on expression of c-fos gene in rat Achilles-derived tendon stem cells. Chin J Rep Reconstr Surg, 2017.

31. Ge R, Wang Z, Zeng Q, Xu X and Olumi AF: F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ 18: 1184-1195, 2011.

32. Otsuka M, Hatakenaka M, Ishigami K and Masuda K: Expression of the c-myc and c-fos genes as a potential indicator of late radiation damage to the kidney. Int J Radiat Oncol Biol Phys 49: 169-173, 2001.

33. Zhou F, Zhang L, Su Y, Zhang J and An Z: Inhibitory effect of artemisinin on the upregulation of c-fos and c-jun gene expression in kidney tissue of diabetic rats. Modern Journal of Integrated Traditional Chinese & Western Medicine 23: 2294-2295, 2014.

34. Yazdi AS and Ghoreschi K: The interleukin-1 family. Adv Exp Med Biol 941: 21-29, 2016.

35. Russai K, Huang H, Sayed N, Strobl M, Roos M, Schmaderer C, Heemann U and Lutz J: Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int 21: 572-580, 2008.

36. Pindjakova J, Hanley SA, Duffy MM, Sutton CE, Weidhofer GA, Miller MN, Nath KA, Mills KH, Ceredig R and Griffin MD: Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction. Kidney Int 81: 379-390, 2012.

37. Wajant H, Pfitzenmaier K and Scheurich P: Tumor necrosis factor signaling. Cell Death Differ 10: 45-65, 2003.

38. Meldrum K, Missiri R, Rink R and Meldrum D: Tumor necrosis factor alpha (TNF) mediates renal tubular cell apoptosis during obstructive uropathy. J Am Coll Surg 197: S91, 2003.

39. Awad AS, You H, Gao T, Cooper TK, Nedospasov SA, Vacher J, Wilkinson PF, Farrell FX and Brian Reeves W: Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury. Kidney Int 88: 722-733, 2015.

40. Shu KH, Lee SH, Cheng CH, Wu MJ and Lian JD: Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Kidney Int 58: 783-789, 2000.

41. World Health Organization; Stuart MC, Kouimtzi M and Hill S (eds): WHO model formulary 2008. World Health Organization, Geneva, 2009.

42. Sattarinezhad E, Panjehshahin MR, Torabinezhad S, Kamali-Sarvestani E, Farjadi S, Pirsalami F and Moezi L: Protective effect of edaravone against cyclosporine-induced chronic nephropathy through antioxidant and nitric oxide modulating pathways in rats. Iran J Med Sci 42: 170-178, 2017.